### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ Origin: Appendix 5 \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13, \ o1/o1/o3, \ o1/o1/o1/o3, \ o1/o1/o1/o3, \ o1/o1/o1/o3, \$ 

Kore Potash Limited	
ABN	
31 108 066 422	

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>+</sup>Class of <sup>+</sup>securities issued or to be issued
- i) Ordinary Shares
- ii) Unlisted Options
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- i) 26,504,000

5,000,000

ii)

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- Same as previously issued Fully Paid Ordinary Shares
- ii) Unlisted Options exercisable at \$0.30 expiring 15 Nov 2019

Do the +securities rank equally in Yes, same as other Fully Paid Ordinary Shares and 4 all respects from the +issue date Unlisted Options exercisable at \$0.30 expiring 15 with an existing \*class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next distribution or dividend, interest payment Issue price or consideration US\$5,000,000 at an issue price of A\$0.25 per share 5 with one free attaching unlisted option for every US\$1 subscribed for Purpose of the issue The funds raised forms part of the overall US\$50m 6 (If issued as consideration for the raising contemplated in the ASX acquisition of assets, clearly announcements dated 1 September 2016 and 11 identify those assets) November 2016. Funds raised will be use for the Definitive Feasibility Study at the Kola Sylvinite Project, drilling at Dougou Extension and for general working capital purposes. 6a Is the entity an +eligible entity No that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6с Number of +securities issued i) 26,504,000 without security holder approval ii) 5,000,000 under rule 7.1 Number of \*securities issued with N/A 6d security holder approval under rule 7.1A Number of +securities issued with N/A 6e security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

10271611/1

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer below	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	27 April 2017	
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	Number 760,298,530	<sup>+</sup> Class Ordinary fully paid shares

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
250,000	Unlisted Options exercisable at \$0.90 expiring 22 May 2017.
6,691,226	Unlisted Options exercisable at \$0.33 expiring 15 April 2018
1,500,000	Unlisted Options exercisable at \$0.33 expiring 26 June 2018
2,263,370	Class B Performance Rights (Emp)
2,666,090	Class C Performance Rights (Emp)
4,500,000	Performance Rights expiring 6 December 2020 (Emp)
12,000,000	Performance Rights expiring 1 March 2021 (Dir)
7,437,500	Performance Rights expiring 1 March 2021 (Dir)
3,000,000	Performance Rights expiring 30 June 2021 (Dir)
50,000,000	Unlisted Options exercisable at \$0.30 expiring 15 Nov 2019

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	

10271611/1

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of	
	acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and will be sent to persons entitled	

27	f the entity has issued options, and the terms entitle option holders to participate on exercise, he date on which notices will be ent to option holders
28	Date rights trading will begin (if pplicable)
29	Date rights trading will end (if pplicable)
30	How do security holders sell their entitlements in full through a broker?
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do security holders dispose of heir entitlements (except by sale hrough a broker)?
33	Issue date
	- Quotation of securities only complete this section if you are applying for quotation of securities
34	Type of securities tick one)
(a)	*Securities described in Part 1
(b)	All other †securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employ incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitie	that have ticked box 34(a)
Addit	onal securities forming a new class of securities
Tick to docume	dicate you are providing the information or s
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities hel by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories
10271611/1 + See cl	pter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37	A copy of any trust deed for the additional *securities		
Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do		
	not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in clause 38)	Number	+Class

#### Quotation agreement

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

......Date: 2 May 2017

Joint Company Secretary

Print name: Henko Vos

== == == ==

10271611/1

Sign here:

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12. Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	433,361,970		
Add the following:			
Number of fully paid *ordinary securities issued in that 12 month period under an	262,740,000		
exception in rule 7.2	13,793,850		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	4,850,060		
Number of partly paid *ordinary securities that became fully paid in that 12 month period			
Note:  Include only ordinary securities here — other classes of equity securities cannot be added  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items			
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-		
"A"	714,745,880		

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	107,211,881
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
<ul> <li>Under an exception in rule 7.2</li> </ul>	19,048,650
Under rule 7.1A	2,900,000 (Unlisted Options)
With security holder approval under rule	26,504,000
7.1 or rule 7.4	5,000,000 (Unlisted Options)
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	53,452,650
Step 4: Subtract "C" from ["A" x "B capacity under rule 7.1	"] to calculate remaining placement
"A" x 0.15	107,211,881
Note: number must be same as shown in Step 2	
Subtract "C"	53,452,650
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	53,759,231 [Note: this is the remaining

#### 10271611/1

Appendix 3B Page 10 04/03/2013

placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 – NOT APPLICABLE

10271611/1

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.